

Global Epidermolysis Bullosa Therapeutics Market Growth 2024-2030

<https://marketpublishers.com/r/G648A267D030EN.html>

Date: February 2024

Pages: 106

Price: US\$ 3,660.00 (Single User License)

ID: G648A267D030EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Epidermolysis Bullosa Therapeutics market size was valued at US\$ 1591 million in 2023. With growing demand in downstream market, the Epidermolysis Bullosa Therapeutics is forecast to a readjusted size of US\$ 2232.5 million by 2030 with a CAGR of 5.0% during review period.

The research report highlights the growth potential of the global Epidermolysis Bullosa Therapeutics market. Epidermolysis Bullosa Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Epidermolysis Bullosa Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Epidermolysis Bullosa Therapeutics market.

Key Features:

The report on Epidermolysis Bullosa Therapeutics market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Epidermolysis Bullosa Therapeutics market. It may include historical data, market segmentation by Type (e.g., EB-201, FCX-007), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Epidermolysis Bullosa Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Epidermolysis Bullosa Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Epidermolysis Bullosa Therapeutics industry. This include advancements in Epidermolysis Bullosa Therapeutics technology, Epidermolysis Bullosa Therapeutics new entrants, Epidermolysis Bullosa Therapeutics new investment, and other innovations that are shaping the future of Epidermolysis Bullosa Therapeutics.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Epidermolysis Bullosa Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Epidermolysis Bullosa Therapeutics product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Epidermolysis Bullosa Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Epidermolysis Bullosa Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Epidermolysis Bullosa Therapeutics market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Epidermolysis Bullosa Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities

for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Epidermolysis Bullosa Therapeutics market.

Market Segmentation:

Epidermolysis Bullosa Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

EB-201

FCX-007

ICX-RHY

INM-750

Others

Segmentation by application

Clinic

Hospital

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Birken AG

Fibrocell Science, Inc.

GlaxoSmithKline Plc

InMed Pharmaceuticals Inc.

Karus Therapeutics Limited

ProQR Therapeutics N.V.

RegeneRx Biopharmaceuticals, Inc.

Scioderm, Inc.

Stratatech Corporation

TWi Pharmaceuticals, Inc.

WAVE Life Sciences Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Epidermolysis Bullosa Therapeutics market?

What factors are driving Epidermolysis Bullosa Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Epidermolysis Bullosa Therapeutics market opportunities vary by end market size?

How does Epidermolysis Bullosa Therapeutics break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Country/Region, 2019, 2023 & 2030

2.2 Epidermolysis Bullosa Therapeutics Segment by Type

- 2.2.1 EB-201
- 2.2.2 FCX-007
- 2.2.3 ICX-RHY
- 2.2.4 INM-750
- 2.2.5 Others

2.3 Epidermolysis Bullosa Therapeutics Sales by Type

- 2.3.1 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)
- 2.3.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Type (2019-2024)

2.4 Epidermolysis Bullosa Therapeutics Segment by Application

- 2.4.1 Clinic
- 2.4.2 Hospital
- 2.4.3 Others

2.5 Epidermolysis Bullosa Therapeutics Sales by Application

- 2.5.1 Global Epidermolysis Bullosa Therapeutics Sale Market Share by Application

(2019-2024)

2.5.2 Global Epidermolysis Bullosa Therapeutics Revenue and Market Share by Application (2019-2024)

2.5.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Application (2019-2024)

3 GLOBAL EPIDERMOLYSIS BULLOSA THERAPEUTICS BY COMPANY

3.1 Global Epidermolysis Bullosa Therapeutics Breakdown Data by Company

3.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Company (2019-2024)

3.1.2 Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2019-2024)

3.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Company (2019-2024)

3.2.1 Global Epidermolysis Bullosa Therapeutics Revenue by Company (2019-2024)

3.2.2 Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company (2019-2024)

3.3 Global Epidermolysis Bullosa Therapeutics Sale Price by Company

3.4 Key Manufacturers Epidermolysis Bullosa Therapeutics Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Epidermolysis Bullosa Therapeutics Product Location Distribution

3.4.2 Players Epidermolysis Bullosa Therapeutics Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

4.1 World Historic Epidermolysis Bullosa Therapeutics Market Size by Geographic Region (2019-2024)

4.1.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Epidermolysis Bullosa Therapeutics Market Size by Country/Region (2019-2024)

4.2.1 Global Epidermolysis Bullosa Therapeutics Annual Sales by Country/Region (2019-2024)

4.2.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue by Country/Region (2019-2024)

4.3 Americas Epidermolysis Bullosa Therapeutics Sales Growth

4.4 APAC Epidermolysis Bullosa Therapeutics Sales Growth

4.5 Europe Epidermolysis Bullosa Therapeutics Sales Growth

4.6 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Growth

5 AMERICAS

5.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country

5.1.1 Americas Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024)

5.1.2 Americas Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024)

5.2 Americas Epidermolysis Bullosa Therapeutics Sales by Type

5.3 Americas Epidermolysis Bullosa Therapeutics Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region

6.1.1 APAC Epidermolysis Bullosa Therapeutics Sales by Region (2019-2024)

6.1.2 APAC Epidermolysis Bullosa Therapeutics Revenue by Region (2019-2024)

6.2 APAC Epidermolysis Bullosa Therapeutics Sales by Type

6.3 APAC Epidermolysis Bullosa Therapeutics Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Epidermolysis Bullosa Therapeutics by Country

7.1.1 Europe Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024)

7.1.2 Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024)

7.2 Europe Epidermolysis Bullosa Therapeutics Sales by Type

7.3 Europe Epidermolysis Bullosa Therapeutics Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Epidermolysis Bullosa Therapeutics by Country

8.1.1 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024)

8.1.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024)

8.2 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Type

8.3 Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Epidermolysis Bullosa Therapeutics

10.3 Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics

10.4 Industry Chain Structure of Epidermolysis Bullosa Therapeutics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Epidermolysis Bullosa Therapeutics Distributors

11.3 Epidermolysis Bullosa Therapeutics Customer

12 WORLD FORECAST REVIEW FOR EPIDERMOLYSIS BULLOSA THERAPEUTICS BY GEOGRAPHIC REGION

12.1 Global Epidermolysis Bullosa Therapeutics Market Size Forecast by Region

12.1.1 Global Epidermolysis Bullosa Therapeutics Forecast by Region (2025-2030)

12.1.2 Global Epidermolysis Bullosa Therapeutics Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Epidermolysis Bullosa Therapeutics Forecast by Type

12.7 Global Epidermolysis Bullosa Therapeutics Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Birken AG

13.1.1 Birken AG Company Information

13.1.2 Birken AG Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.1.3 Birken AG Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Birken AG Main Business Overview

13.1.5 Birken AG Latest Developments

13.2 Fibrocell Science, Inc.

13.2.1 Fibrocell Science, Inc. Company Information

13.2.2 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.2.3 Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.2.4 Fibrocell Science, Inc. Main Business Overview
- 13.2.5 Fibrocell Science, Inc. Latest Developments
- 13.3 GlaxoSmithKline Plc
 - 13.3.1 GlaxoSmithKline Plc Company Information
 - 13.3.2 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
 - 13.3.3 GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.3.4 GlaxoSmithKline Plc Main Business Overview
 - 13.3.5 GlaxoSmithKline Plc Latest Developments
- 13.4 InMed Pharmaceuticals Inc.
 - 13.4.1 InMed Pharmaceuticals Inc. Company Information
 - 13.4.2 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
 - 13.4.3 InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 InMed Pharmaceuticals Inc. Main Business Overview
 - 13.4.5 InMed Pharmaceuticals Inc. Latest Developments
- 13.5 Karus Therapeutics Limited
 - 13.5.1 Karus Therapeutics Limited Company Information
 - 13.5.2 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
 - 13.5.3 Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Karus Therapeutics Limited Main Business Overview
 - 13.5.5 Karus Therapeutics Limited Latest Developments
- 13.6 ProQR Therapeutics N.V.
 - 13.6.1 ProQR Therapeutics N.V. Company Information
 - 13.6.2 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
 - 13.6.3 ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 ProQR Therapeutics N.V. Main Business Overview
 - 13.6.5 ProQR Therapeutics N.V. Latest Developments
- 13.7 RegeneRx Biopharmaceuticals, Inc.
 - 13.7.1 RegeneRx Biopharmaceuticals, Inc. Company Information
 - 13.7.2 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
 - 13.7.3 RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales,

Revenue, Price and Gross Margin (2019-2024)

13.7.4 RegeneRx Biopharmaceuticals, Inc. Main Business Overview

13.7.5 RegeneRx Biopharmaceuticals, Inc. Latest Developments

13.8 Scioderm, Inc.

13.8.1 Scioderm, Inc. Company Information

13.8.2 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.8.3 Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Scioderm, Inc. Main Business Overview

13.8.5 Scioderm, Inc. Latest Developments

13.9 Stratatech Corporation

13.9.1 Stratatech Corporation Company Information

13.9.2 Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.9.3 Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Stratatech Corporation Main Business Overview

13.9.5 Stratatech Corporation Latest Developments

13.10 TWi Pharmaceuticals, Inc.

13.10.1 TWi Pharmaceuticals, Inc. Company Information

13.10.2 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.10.3 TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 TWi Pharmaceuticals, Inc. Main Business Overview

13.10.5 TWi Pharmaceuticals, Inc. Latest Developments

13.11 WAVE Life Sciences Ltd.

13.11.1 WAVE Life Sciences Ltd. Company Information

13.11.2 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

13.11.3 WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales, Revenue, Price and Gross Margin (2019-2024)

13.11.4 WAVE Life Sciences Ltd. Main Business Overview

13.11.5 WAVE Life Sciences Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Epidermolysis Bullosa Therapeutics Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Epidermolysis Bullosa Therapeutics Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of EB-201

Table 4. Major Players of FCX-007

Table 5. Major Players of ICX-RHY

Table 6. Major Players of INM-750

Table 7. Major Players of Others

Table 8. Global Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024) & (K Pcs)

Table 9. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)

Table 10. Global Epidermolysis Bullosa Therapeutics Revenue by Type (2019-2024) & (\$ million)

Table 11. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2019-2024)

Table 12. Global Epidermolysis Bullosa Therapeutics Sale Price by Type (2019-2024) & (USD/Pcs)

Table 13. Global Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024) & (K Pcs)

Table 14. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2024)

Table 15. Global Epidermolysis Bullosa Therapeutics Revenue by Application (2019-2024)

Table 16. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application (2019-2024)

Table 17. Global Epidermolysis Bullosa Therapeutics Sale Price by Application (2019-2024) & (USD/Pcs)

Table 18. Global Epidermolysis Bullosa Therapeutics Sales by Company (2019-2024) & (K Pcs)

Table 19. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company (2019-2024)

Table 20. Global Epidermolysis Bullosa Therapeutics Revenue by Company (2019-2024) (\$ Millions)

Table 21. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company (2019-2024)

Table 22. Global Epidermolysis Bullosa Therapeutics Sale Price by Company (2019-2024) & (USD/Pcs)

Table 23. Key Manufacturers Epidermolysis Bullosa Therapeutics Producing Area Distribution and Sales Area

Table 24. Players Epidermolysis Bullosa Therapeutics Products Offered

Table 25. Epidermolysis Bullosa Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Epidermolysis Bullosa Therapeutics Sales by Geographic Region (2019-2024) & (K Pcs)

Table 29. Global Epidermolysis Bullosa Therapeutics Sales Market Share Geographic Region (2019-2024)

Table 30. Global Epidermolysis Bullosa Therapeutics Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 31. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Geographic Region (2019-2024)

Table 32. Global Epidermolysis Bullosa Therapeutics Sales by Country/Region (2019-2024) & (K Pcs)

Table 33. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Country/Region (2019-2024)

Table 34. Global Epidermolysis Bullosa Therapeutics Revenue by Country/Region (2019-2024) & (\$ millions)

Table 35. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Country/Region (2019-2024)

Table 36. Americas Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024) & (K Pcs)

Table 37. Americas Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2019-2024)

Table 38. Americas Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024) & (\$ Millions)

Table 39. Americas Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2019-2024)

Table 40. Americas Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024) & (K Pcs)

Table 41. Americas Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024) & (K Pcs)

Table 42. APAC Epidermolysis Bullosa Therapeutics Sales by Region (2019-2024) & (K Pcs)

Table 43. APAC Epidermolysis Bullosa Therapeutics Sales Market Share by Region (2019-2024)

Table 44. APAC Epidermolysis Bullosa Therapeutics Revenue by Region (2019-2024) & (\$ Millions)

Table 45. APAC Epidermolysis Bullosa Therapeutics Revenue Market Share by Region (2019-2024)

Table 46. APAC Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024) & (K Pcs)

Table 47. APAC Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024) & (K Pcs)

Table 48. Europe Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024) & (K Pcs)

Table 49. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2019-2024)

Table 50. Europe Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024) & (\$ Millions)

Table 51. Europe Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2019-2024)

Table 52. Europe Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024) & (K Pcs)

Table 53. Europe Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024) & (K Pcs)

Table 54. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Country (2019-2024) & (K Pcs)

Table 55. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Market Share by Country (2019-2024)

Table 56. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue by Country (2019-2024) & (\$ Millions)

Table 57. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue Market Share by Country (2019-2024)

Table 58. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Type (2019-2024) & (K Pcs)

Table 59. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales by Application (2019-2024) & (K Pcs)

Table 60. Key Market Drivers & Growth Opportunities of Epidermolysis Bullosa Therapeutics

Table 61. Key Market Challenges & Risks of Epidermolysis Bullosa Therapeutics

Table 62. Key Industry Trends of Epidermolysis Bullosa Therapeutics
Table 63. Epidermolysis Bullosa Therapeutics Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Epidermolysis Bullosa Therapeutics Distributors List
Table 66. Epidermolysis Bullosa Therapeutics Customer List
Table 67. Global Epidermolysis Bullosa Therapeutics Sales Forecast by Region (2025-2030) & (K Pcs)
Table 68. Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Region (2025-2030) & (\$ millions)
Table 69. Americas Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2025-2030) & (K Pcs)
Table 70. Americas Epidermolysis Bullosa Therapeutics Revenue Forecast by Country (2025-2030) & (\$ millions)
Table 71. APAC Epidermolysis Bullosa Therapeutics Sales Forecast by Region (2025-2030) & (K Pcs)
Table 72. APAC Epidermolysis Bullosa Therapeutics Revenue Forecast by Region (2025-2030) & (\$ millions)
Table 73. Europe Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2025-2030) & (K Pcs)
Table 74. Europe Epidermolysis Bullosa Therapeutics Revenue Forecast by Country (2025-2030) & (\$ millions)
Table 75. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Forecast by Country (2025-2030) & (K Pcs)
Table 76. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue Forecast by Country (2025-2030) & (\$ millions)
Table 77. Global Epidermolysis Bullosa Therapeutics Sales Forecast by Type (2025-2030) & (K Pcs)
Table 78. Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Type (2025-2030) & (\$ Millions)
Table 79. Global Epidermolysis Bullosa Therapeutics Sales Forecast by Application (2025-2030) & (K Pcs)
Table 80. Global Epidermolysis Bullosa Therapeutics Revenue Forecast by Application (2025-2030) & (\$ Millions)
Table 81. Birken AG Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors
Table 82. Birken AG Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications
Table 83. Birken AG Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 84. Birken AG Main Business

Table 85. Birken AG Latest Developments

Table 86. Fibrocell Science, Inc. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 87. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 88. Fibrocell Science, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 89. Fibrocell Science, Inc. Main Business

Table 90. Fibrocell Science, Inc. Latest Developments

Table 91. GlaxoSmithKline Plc Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 92. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 93. GlaxoSmithKline Plc Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 94. GlaxoSmithKline Plc Main Business

Table 95. GlaxoSmithKline Plc Latest Developments

Table 96. InMed Pharmaceuticals Inc. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 97. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 98. InMed Pharmaceuticals Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 99. InMed Pharmaceuticals Inc. Main Business

Table 100. InMed Pharmaceuticals Inc. Latest Developments

Table 101. Karus Therapeutics Limited Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 102. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 103. Karus Therapeutics Limited Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 104. Karus Therapeutics Limited Main Business

Table 105. Karus Therapeutics Limited Latest Developments

Table 106. ProQR Therapeutics N.V. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 107. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 108. ProQR Therapeutics N.V. Epidermolysis Bullosa Therapeutics Sales (K

Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 109. ProQR Therapeutics N.V. Main Business

Table 110. ProQR Therapeutics N.V. Latest Developments

Table 111. RegeneRx Biopharmaceuticals, Inc. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 112. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 113. RegeneRx Biopharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 114. RegeneRx Biopharmaceuticals, Inc. Main Business

Table 115. RegeneRx Biopharmaceuticals, Inc. Latest Developments

Table 116. Scioderm, Inc. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 117. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 118. Scioderm, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 119. Scioderm, Inc. Main Business

Table 120. Scioderm, Inc. Latest Developments

Table 121. Stratatech Corporation Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 122. Stratatech Corporation Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 123. Stratatech Corporation Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 124. Stratatech Corporation Main Business

Table 125. Stratatech Corporation Latest Developments

Table 126. TWi Pharmaceuticals, Inc. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 127. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 128. TWi Pharmaceuticals, Inc. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 129. TWi Pharmaceuticals, Inc. Main Business

Table 130. TWi Pharmaceuticals, Inc. Latest Developments

Table 131. WAVE Life Sciences Ltd. Basic Information, Epidermolysis Bullosa Therapeutics Manufacturing Base, Sales Area and Its Competitors

Table 132. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Product Portfolios and Specifications

Table 133. WAVE Life Sciences Ltd. Epidermolysis Bullosa Therapeutics Sales (K Pcs), Revenue (\$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)

Table 134. WAVE Life Sciences Ltd. Main Business

Table 135. WAVE Life Sciences Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Epidermolysis Bullosa Therapeutics
- Figure 2. Epidermolysis Bullosa Therapeutics Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Epidermolysis Bullosa Therapeutics Sales Growth Rate 2019-2030 (K Pcs)
- Figure 7. Global Epidermolysis Bullosa Therapeutics Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Epidermolysis Bullosa Therapeutics Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of EB-201
- Figure 10. Product Picture of FCX-007
- Figure 11. Product Picture of ICX-RHY
- Figure 12. Product Picture of INM-750
- Figure 13. Product Picture of Others
- Figure 14. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Type in 2023
- Figure 15. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Type (2019-2024)
- Figure 16. Epidermolysis Bullosa Therapeutics Consumed in Clinic
- Figure 17. Global Epidermolysis Bullosa Therapeutics Market: Clinic (2019-2024) & (K Pcs)
- Figure 18. Epidermolysis Bullosa Therapeutics Consumed in Hospital
- Figure 19. Global Epidermolysis Bullosa Therapeutics Market: Hospital (2019-2024) & (K Pcs)
- Figure 20. Epidermolysis Bullosa Therapeutics Consumed in Others
- Figure 21. Global Epidermolysis Bullosa Therapeutics Market: Others (2019-2024) & (K Pcs)
- Figure 22. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2023)
- Figure 23. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Application in 2023
- Figure 24. Epidermolysis Bullosa Therapeutics Sales Market by Company in 2023 (K Pcs)

Figure 25. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Company in 2023

Figure 26. Epidermolysis Bullosa Therapeutics Revenue Market by Company in 2023 (\$ Million)

Figure 27. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Company in 2023

Figure 28. Global Epidermolysis Bullosa Therapeutics Sales Market Share by Geographic Region (2019-2024)

Figure 29. Global Epidermolysis Bullosa Therapeutics Revenue Market Share by Geographic Region in 2023

Figure 30. Americas Epidermolysis Bullosa Therapeutics Sales 2019-2024 (K Pcs)

Figure 31. Americas Epidermolysis Bullosa Therapeutics Revenue 2019-2024 (\$ Millions)

Figure 32. APAC Epidermolysis Bullosa Therapeutics Sales 2019-2024 (K Pcs)

Figure 33. APAC Epidermolysis Bullosa Therapeutics Revenue 2019-2024 (\$ Millions)

Figure 34. Europe Epidermolysis Bullosa Therapeutics Sales 2019-2024 (K Pcs)

Figure 35. Europe Epidermolysis Bullosa Therapeutics Revenue 2019-2024 (\$ Millions)

Figure 36. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales 2019-2024 (K Pcs)

Figure 37. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue 2019-2024 (\$ Millions)

Figure 38. Americas Epidermolysis Bullosa Therapeutics Sales Market Share by Country in 2023

Figure 39. Americas Epidermolysis Bullosa Therapeutics Revenue Market Share by Country in 2023

Figure 40. Americas Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)

Figure 41. Americas Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2024)

Figure 42. United States Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 43. Canada Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 44. Mexico Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 45. Brazil Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 46. APAC Epidermolysis Bullosa Therapeutics Sales Market Share by Region in 2023

Figure 47. APAC Epidermolysis Bullosa Therapeutics Revenue Market Share by Regions in 2023

Figure 48. APAC Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)

Figure 49. APAC Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2024)

Figure 50. China Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 51. Japan Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 52. South Korea Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 53. Southeast Asia Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 54. India Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 55. Australia Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 56. China Taiwan Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 57. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Country in 2023

Figure 58. Europe Epidermolysis Bullosa Therapeutics Revenue Market Share by Country in 2023

Figure 59. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)

Figure 60. Europe Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2024)

Figure 61. Germany Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 62. France Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 63. UK Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 64. Italy Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 65. Russia Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 66. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Market Share

by Country in 2023

Figure 67. Middle East & Africa Epidermolysis Bullosa Therapeutics Revenue Market Share by Country in 2023

Figure 68. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Market Share by Type (2019-2024)

Figure 69. Middle East & Africa Epidermolysis Bullosa Therapeutics Sales Market Share by Application (2019-2024)

Figure 70. Egypt Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 71. South Africa Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 72. Israel Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 73. Turkey Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 74. GCC Country Epidermolysis Bullosa Therapeutics Revenue Growth 2019-2024 (\$ Millions)

Figure 75. Manufacturing Cost Structure Analysis of Epidermolysis Bullosa Therapeutics in 2023

Figure 76. Manufacturing Process Analysis of Epidermolysis Bullosa Therapeutics

Figure 77. Industry Chain Structure of Epidermolysis Bullosa Therapeutics

Figure 78. Channels of Distribution

Figure 79. Global Epidermolysis Bullosa Therapeutics Sales Market Forecast by Region (2025-2030)

Figure 80. Global Epidermolysis Bullosa Therapeutics Revenue Market Share Forecast by Region (2025-2030)

Figure 81. Global Epidermolysis Bullosa Therapeutics Sales Market Share Forecast by Type (2025-2030)

Figure 82. Global Epidermolysis Bullosa Therapeutics Revenue Market Share Forecast by Type (2025-2030)

Figure 83. Global Epidermolysis Bullosa Therapeutics Sales Market Share Forecast by Application (2025-2030)

Figure 84. Global Epidermolysis Bullosa Therapeutics Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Epidermolysis Bullosa Therapeutics Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G648A267D030EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G648A267D030EN.html>